Peter Hampson
Research Subjects
Research Interests
Peter Hampson has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Phillip P. McGarry
University of Tennessee
2 shared publicationsAnita Ryningen
Division for Haematology, Department of Medicine, Haukeland University Hospital and the University of Bergen, Bergen, Norway
1 shared publication- Astrid Olsnes Kittang
Section for Hematology, Institute of Medicine, University of Bergen, Bergen, Norway
1 shared publication - Bjørn Tore Gjertsen
Haukeland University Hospital Bergen Norway
1 shared publication - Einar Klæboe Kristoffersen
Laboratory Medicine and Pathology, Department of Immunology and Transfusion Medicine Haukeland University Hospital Bergen Norway
1 shared publication - Elisabeth Ersvær
University of Inland Norway, Hamar
1 shared publication
Latest Publications
- 12 March 2025
- Published by SAGE Publications in Theory & Psychology
- Vol. 35 (2) , 185-205
Phronesis, affordance, and executive function: Situating values within moral psychology
The Aristotelian virtue phronesis economically yet comprehensively integrates moral perception with moral action. Though aspects of phronesis characterize many complex skills, we claim that, in the right circumstances, thinking and acting phronetically can facilitate fast and slow moral choices and be involved in the governance of both intuitively guided and intentional moral action. Phronesis , working with values and affordances, reveals the fittingness of potential actions to the moral actor, indicating which action is best. By relating (though not directly equating) aspects of phronesis to components of executive function, we integrate work whose potential relevance for moral psychology has been largely overlooked.
- 12 March 2025
- Published by SAGE Publications in Theory & Psychology
- Vol. 35 (2) , 185-205
Phronesis, affordance, and executive function: Situating values within moral psychology
The Aristotelian virtue phronesis economically yet comprehensively integrates moral perception with moral action. Though aspects of phronesis characterize many complex skills, we claim that, in the right circumstances, thinking and acting phronetically can facilitate fast and slow moral choices and be involved in the governance of both intuitively guided and intentional moral action. Phronesis , working with values and affordances, reveals the fittingness of potential actions to the moral actor, indicating which action is best. By relating (though not directly equating) aspects of phronesis to components of executive function, we integrate work whose potential relevance for moral psychology has been largely overlooked.
- 1 January 2022
- Published by Cambridge University Press (CUP) in New Blackfriars
- Vol. 103 (1103) , 153-156
Being Human: Bodies, Minds, Persons by Rowan Williams, SCM Press, London, 2018, pp. x + 128, £9.99, pbk
- 1 January 2022
- Published by Cambridge University Press (CUP) in New Blackfriars
- Vol. 103 (1103) , 153-156
Being Human: Bodies, Minds, Persons by Rowan Williams, SCM Press, London, 2018, pp. x + 128, £9.99, pbk
- Open Access
- 2 July 2021
- Published by SAGE Publications in Theory & Psychology
- Vol. 31 (4) , 513-532
Moral affordance, moral expertise, and virtue
We extend “4E” cognition to moral psychology. Since acting on affordances typically requires expertise, moral expertise, or virtue, is needed to act on moral affordances and to shape moral agency. Ethical rules and codes, often selected through a process of constraint satisfaction, are also involved in the detection and selection of moral affordances. We argue that individuals who act prudently possess moral expertise that allows them to remain in the “metastable zone” between mind and world, giving them an optimal grip on moral affordances and permitting wise judgement and action. We show how this can be explained via a noncognitivist, affordance-based account of the virtue phronesis (prudence). Our overall approach creates space for reciprocally causal accounts and prospection in explanations of human moral activity.
- 2 July 2021
- Published by SAGE Publications in Theory & Psychology
- Vol. 31 (4) , 513-532
Open AccessMoral affordance, moral expertise, and virtue
We extend “4E” cognition to moral psychology. Since acting on affordances typically requires expertise, moral expertise, or virtue, is needed to act on moral affordances and to shape moral agency. Ethical rules and codes, often selected through a process of constraint satisfaction, are also involved in the detection and selection of moral affordances. We argue that individuals who act prudently possess moral expertise that allows them to remain in the “metastable zone” between mind and world, giving them an optimal grip on moral affordances and permitting wise judgement and action. We show how this can be explained via a noncognitivist, affordance-based account of the virtue phronesis (prudence). Our overall approach creates space for reciprocally causal accounts and prospection in explanations of human moral activity.
- 11 April 2021
- Published by Cambridge University Press (CUP) in New Blackfriars
- Vol. 102 (1099) , 430-432
SCM Studyguide to Religious and Spiritual Experience by Jeff Astley, SCM Press, London, 2020, pp. xi + 306, £19.99, pbk
- 11 April 2021
- Published by Cambridge University Press (CUP) in New Blackfriars
- Vol. 102 (1099) , 430-432
SCM Studyguide to Religious and Spiritual Experience by Jeff Astley, SCM Press, London, 2020, pp. xi + 306, £19.99, pbk
- Open Access
- 2 June 2009
- Published by Wiley in British Journal of Haematology
- Vol. 145 (6) , 761-774
The protein kinase C agonist PEP005 increases NF‐κB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells
Summary: Acute myeloid leukaemia (AML) cells show constitutive release of several chemokines that occurs in three major clusters: (I) chemokine (C‐C motif) ligand (CCL)2–4/chemokine (C‐X‐C motif) ligand (CXCL)1/8, (II) CCL5/CXCL9–11 and (III) CCL13/17/22/24/CXCL5. Ingenol‐3‐angelate (PEP005) is an activator of protein kinase C and has antileukaemic and immunostimulatory effects in AML. We investigated primary AML cells derived from 35 unselected patients and determined that PEP005 caused a dose‐dependent increase in the release of chemokines from clusters I and II, including several T cell chemotactic chemokines. The release of granulocyte‐macrophage colony‐stimulating factor and hepatocyte growth factor was also increased. CCL2–4/CXCL1/8 release correlated with nuclear factor (NF)‐κB expression in untreated AML cells, and PEP005‐induced chemokine production was associated with further increases in the expression of the NF‐κB subunits p50, p52 and p65. Increased DNA binding of NF‐κB was observed during exposure to PEP005, and the specific NF‐κB inhibitor BMS‐345541 reduced constitutive chemokine release even in the presence of PEP005. Finally, PEP005 decreased expression of stem cell markers (CD117, CXCR4) and increased lineage‐associated CD11b and CD14 expression. To conclude, PEP005 has a unique functional pharmacological profile in human AML. Previous studies have described proapoptotic and T cell stimulatory effects and the present study describes additional T cell chemotactic and differentiation‐inducing effects.
- 2 June 2009
- Published by Wiley in British Journal of Haematology
- Vol. 145 (6) , 761-774
Open AccessThe protein kinase C agonist PEP005 increases NF‐κB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells
Summary: Acute myeloid leukaemia (AML) cells show constitutive release of several chemokines that occurs in three major clusters: (I) chemokine (C‐C motif) ligand (CCL)2–4/chemokine (C‐X‐C motif) ligand (CXCL)1/8, (II) CCL5/CXCL9–11 and (III) CCL13/17/22/24/CXCL5. Ingenol‐3‐angelate (PEP005) is an activator of protein kinase C and has antileukaemic and immunostimulatory effects in AML. We investigated primary AML cells derived from 35 unselected patients and determined that PEP005 caused a dose‐dependent increase in the release of chemokines from clusters I and II, including several T cell chemotactic chemokines. The release of granulocyte‐macrophage colony‐stimulating factor and hepatocyte growth factor was also increased. CCL2–4/CXCL1/8 release correlated with nuclear factor (NF)‐κB expression in untreated AML cells, and PEP005‐induced chemokine production was associated with further increases in the expression of the NF‐κB subunits p50, p52 and p65. Increased DNA binding of NF‐κB was observed during exposure to PEP005, and the specific NF‐κB inhibitor BMS‐345541 reduced constitutive chemokine release even in the presence of PEP005. Finally, PEP005 decreased expression of stem cell markers (CD117, CXCR4) and increased lineage‐associated CD11b and CD14 expression. To conclude, PEP005 has a unique functional pharmacological profile in human AML. Previous studies have described proapoptotic and T cell stimulatory effects and the present study describes additional T cell chemotactic and differentiation‐inducing effects.